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Epithelial ovarian cancer (EOC) is a rather rare but lethal disease that is usually diagnosed
at an advanced stage; this is due to a lack of early diagnostic markers. At the
time being, less than a quarter of patients are diagnosed when the tumor has not
metastasized yet. In previous work, we demonstrated that antennarity, fucosylation,
and sialylation increased in EOC patients and built a glycan-based score that was able
to diagnose EOC better than CA125, the routine diagnostic marker, does. To date,
little attention had been paid to the sialic acid linkages of N-glycans in the context of
blood biomarker research. In this work, the sialic acid linkages of the serum glycome of
ovarian cancer patients were investigated for the first time by MALDI-TOF-MS. To this
end, we released N-glycans, derivatized sialic acids solely in a linkage-specific way and
measured glycome profiles by MALDI-TOF mass spectrometry. A statistically significant
decrease was observed between late stage patients and controls or early stage patients
for high-mannose, hybrid-type, complex-type asialylated, bi, tri- and tetraantennary
sialylated structures. A significant decrease of monosialylated monoantennary N-glycan
structures was observed in early and late stage EOC when compared to healthy controls.
Statistically significant increases were observed in early and late stage patients compared
to controls for tri, tetraantennary fucosylated structures, afucosylated, and fucosylated
triantennary structures taken as α-2,3-linked/α-2,6-linked sialic acid ratio. Moreover, all
afucosylated and fucosylated structures taken as α-2,3-linked/α-2,6-linked sialic acid
ratio and the α-2,3-linked/α-2,6-linked sialic acid ratio of all sialylated structures were
increased significantly for early and late stage EOC patients when compared to healthy
controls. Finally, ROC curves were built for the most significant glycan combinations
and we were able to show that the serum glycome sialic acid ratio could enhance
ovarian cancer diagnosis as sialic acid linkage modulations arise even in early stage
ovarian cancer.
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INTRODUCTION
Ovarian cancer was among five leading cancer types in cancer deaths in women in United States
in 2017 (1) with estimated 14,800 ovarian cancer deaths and 22,440 new cases. The 5-year relative
survival rate ranges from 92% in early stage to only 29% in later stages. Currently, only about 20–
25% of ovarian cancer patients are diagnosed in early stages (2). Early diagnosis is therefore crucial
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for the long-term survival rate, however 60% of cases in
United States between 2006 and 20012 were of late stage (1).
There are three types of cells, from which most of benign and
malignant ovarian tumors originate, namely epithelial, stromal
and germ, with epithelial being the most common (>90%) (3).
The routinely used tumor marker for ovarian cancer CA125
shows specificity of 94–98.5%, but low sensitivity (50–62% for
early stages of epithelial ovarian cancer) (4). Since there are no
early warning signs, there is a pressing need for improvements
in early stage diagnostics (5). Newer biomarkers have been
proposed and used, such as HE4, which shows better sensitivity
than CA125 in terms of distinguishing benign disease from
malignant tumor (6). However, the most promising approach
seems to be the use of multi-factor diagnostics, such as a
combination of CA125, HE4 and so-called Symptom index (SI)
(7), which has a sensitivity of 84% and a specificity of 98.5% (8).
Alternative methods for early ovarian cancer diagnosis have been
proposed in the last decade, such as microRNA (9), protein panel
screening (10, 11) and bioinformatic tools (12).
For the potential improvements in ovarian cancer diagnostics,
there is a need to understand causes and pathological alterations
of this malignancy. Glycosylation plays an important role
in biological processes, such as cell recognition, cell-cell
interactions, cell-cell communication and adhesion (13). On
human glycoproteins, sialic acids are either α-2,3- or α-2,6-
linked to galactoses and are the most exposed monosaccharides
to the outer environment, and as such participate in biological
processes including cancerogenesis (14). Correlation were made
between increased sialylation and ovarian cancer stages (5, 15–
17), however, the linkage type has never been investigated
in detail.
Biskup et al. recently identified characteristic changes of the
serum glycome that were combined in a score named GLYCOV
that could diagnose primary epithelial ovarian cancer in a better
way than CA125 (5, 17). GLYCOV contains seven sialylated N-
glycans but the type of sialic acid linkage has not been studied yet.
A cohort of 110 patients including early (FIGO stages I+ II) and
late stages (FIGO III and IV) as well as age-matched controls was
enrolled in this work. Glycoproteins from serumwere released by
PNGase F. Thereafter, the N-glycan pool was derivatized using
linkage-specific labeling and measured by MALDI-TOF-MS in




Serum samples from 110 women aged 32–81 years (mean= 57.1,
median = 55.5 years) were used in this study (Table 1). There
were 77 samples from primary serous ovarian cancer patients of
epithelial origin and 33 healthy controls. Healthy controls were
women who were free from cancer, liver or kidney insufficiency,
inflammatory diseases or pregnancy. Blood was collected as a
part of the Tumor Bank Ovarian Cancer project (http://www.
toc-network.de/), where information about the FIGO stage was
obtained. The Charité Medical University approved the use
of the samples (EA4/073/06 and EA1/285/09). Clot activator
serum tubes (Vacutainer, BD, Medical-Pharmaceutical System,
NJ, USA) were used for collection. Blood was allowed to clot for
a minimum of 30min up to 2 h at room temperature and serum
was separated by centrifugation at 1,200 g for 15min. The CA125
II immunoassay was used to measure CA125 on a COBAS 6000
analyser (Roche Diagnostics, Germany). Serum was aliquoted
and stored at−80◦C until the time of glycan analysis.
N-Glycan Release
Two microliters of human serum were denatured for 10min
at 50◦C in the presence of four microliters of 1% SDS (w/w)
(Merck Millipore, Germany). Thereafter, four microliters of a
releasing solution containing 2% NP-40 (Calbiochem, CA, USA)
(w/w) and 0.5 mU PNGase F (EC 3.5.152; Roche Applied Science,
Indianapolis, IN) in 2.5 × PBS (10xPBS containing 57 g/L
Na2HPO4 × 2H2O, 5 g/L KH2PO4, and 85 g/L NaCl, pH 7.4)
were added to the samples and incubated for 5 h at 37◦C. Samples
were then stored at−20◦C until sialic acids were labeled.
Sialic Acid Derivatization
An (α2-3) and (α2-6)-linkage specific sialic acid derivatization
was performed. To one microliter of N-glycan release digest
were added 10 µl of reaction mixture consisting of 250mM
dimethylamine, 500mM 1-hydroxybenzotriazole hydrate,
250mM 1-ethyl-3-(3-(dimethylamino)propyl) carbodiimide
in DMSO) and incubated for 2.5 h at 60◦C. This step resulted
in the dimethylamidation of the carboxyl groups of 2,6-linked
sialic acids whereas the carboxyl groups of 2,3-linked sialic acids
reacted with the adjacent galactoses to form an unstable lactone.
Then, four microliters of 28% ammonium hydroxide were added
and samples were incubated for additional 2.5 h at 60◦C, which
resulted in the hydrolysis of lactones into amides (18). Samples
were then adjusted to 92% ACN and transferred to −20◦C for
15min prior to purification.
Purification (19)
First, each well of an AcroPrepTM Advance 96-well filter plate
containing a 0.45µmGHP filter membrane was washed with 200
µl of 70% cold ethanol, followed by 3× 200µl MilliQ water and 3
× 200 µl of 96% ACN. Samples were then applied and incubated
for 10min, after which a low vacuum was applied to ensure a
slow flow through the membrane. Each well was then washed
with 3 × 200 µl of cold 96% ACN. Elution of N-glycans from
the plate was performed by addition of 2× 50 µl of MilliQ water.
Samples were then dried in a vacuum centrifuge and stored until
MALDI-TOF-MS measurement.
MALDI-TOF-MS and Data Analysis
MALDI-TOF-MS spectra were recorded on an Ultraflex III
mass spectrometer (Bruker Daltonics, Bremen, Germany)
equipped with Smartbeam laser (100Hz laser frequency)
in reflectron positive mode as a sum of 2500 laser shots in
the mass range 1,200–5,000 Da using 25 kV accelerating
voltage and ion suppression bellow 1,190 Da. Raw spectra
were exported as ASCII text files and Massy Tools script
was first used to re-calibrate the obtained spectra using
list of 10 glycan masses (N4H3F1, N4H4F1, N4H5D1,
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TABLE 1 | Demographics of samples used in this study. CA125 are shown as kU/L.
Stage Control N = 33 Early stage Late stage
FIGO stage I N = 10 FIGO stage II N = 9 FIGO Stage III N = 43 FIGO Stage IV N = 15
Demographics Age CA125 Age CA125 Age CA125 Age CA125 Age CA125
Mean 52.0 14.5 57.6 514.9 57.4 300.6 59.9 1503.6 59.9 2065.3
Median 50.0 12.0 59.5 28.5 53.0 190.0 60.0 616.0 58.0 1195.0
Range 40–81 6–38 48–67 6–4841 40–78 23–851 35–79 11–8094 32–81 6–14310
N4H5D1F1, N4H5D1A1, N4H5D2, N4H5D2F1, N5H6D2A1,
N5H6D2A1F1, N6H7D2A2).
The program mMass was then used to sum all spectra from
each sample (n = 4) leading to a sensitivity increase especially
in the high-mass region. The Massy Tools Python script (20)
was then used on these summed spectra for a targeted peak
extraction of background subtracted analyte areas of 100 glycan
structures. The output of targeted peak extraction was then
processed further, by removing all structures, which had signal-
to-noise ratio (S/N)<9 formore than 90% of all collected spectra.
Additionally, all these structures were evaluated for separate
sample groups and only structures, which appeared in more than
one third of samples in at least a single sample group, were used
for statistical analysis, resulting in areas under the curve for 72
N-glycan peaks. The extracted values were then normalized so
that the intensity of the peak at m/z 2299.9 (H4H5D2) was set to
100%. As a result of this approach, the variance of this structure
could not be statistically tested.
Glycan Traits and Statistical Analysis
Total intensities of specific glycan traits, namely high-
mannosylation, fucosylation, linkage-specific sialylation
and antennarity, were calculated as a sum of intensities of
all respective structures (Supplementary Table 1). For the
calculation of sialylation traits, firstly, relative sialylation
intensities were calculated for each structure as shown in
Equation 1:
S (degree of sialylation) = Dn + An
relative α-2,6 sialylation = (Dn/S)
∗ (relative
intensity NnHnDnAnFn)
relative α-2,3 sialylation = (An/S)
∗ (relative
intensity NnHnDnAnFn)
where H = hexose, N = N-acetylhexosamine, A = α-2,3-linked
sialic acid, D= α-2,6-linked sialic acid, F= fucose
Then, total sialylation traits were calculated as a sum of relative
sialylation intensities of the respective structures. For example,
the total α-2,3-sialylation of triantennary fucosylated N-glycans
was calculated according to Equation 2:
Fucosylated complex triantennary α-2,3 =
(1/2)∗(N5H5D1A1F1 + N5H6D1A1F1) +
(2/3)∗(N5H6D1A2F1)+ (1/3)∗(N5H6D2A1F1)
where H = hexose, N = N-acetylhexosamine, A = α-2,3-linked
sialic acid, D= α-2,6-linked sialic acid, F= fucose
Additionally, a ratio between α-2,3 and α-2,6 sialylation
was calculated for each grouped N-glycans, which included all
complex sialylated structures (Supplementary Table 1).
Means and standard deviations were calculated for FIGO
stages and for grouped ovarian cancer stages (healthy controls,
early stage = FIGO I + FIGO II, late stage = FIGO III +
FIGO IV). The Shapiro-Wilk test showed that the data were not
normally distributed and therefore non-parametric tests were
used for further statistical evaluation. The Jonckheere-Terpstra
test (TJT) was selected since the independent variables consisted
of three ordinal groups of cancer progression (healthy control
< early stage < late stage), while the dependent variables were
measured on a continuous level, and there was no relationship
between samples in various groups. The TJT was used to
test the null hypothesis that the distribution of individual N-
glycans was the same across ovarian cancer stages. In other
words, it was tested if there is a positive or negative trend
during cancer progression. The null hypothesis was rejected
when p< 0.05.
RESULTS
In this work, the sialic acid linkages of the serum glycome of
ovarian cancer patients were investigated for the first time by
MALDI-TOF-MS. To this end, serum N-glycans from ovarian
cancer patients and age-matched healthy controls were released
after serum protein denaturation. A linkage-specific sialic acid
derivatization was performed, whereby the carboxyl groups of
2,6-linked sialic acids were dimethylamidated and the carboxyl
groups of 2,3-linked sialic acids were first lactonized then
amidated (18). Samples were finally purified using HILIC 96-well
plates, dried by vacuum concentration andmeasured byMALDI-
TOF-MS.
N-glycan Features of the Total Serum
Glycome
Seventy-one N-glycan structures were detected (Figure 1),
four were high-mannoses, thirteen were asialylated
complex-type structures, of which seven were fucosylated.
Due to sialic acid linkage-specific labeling, overall 54
different sialylated N-glycans were detected, of which 24
were fucosylated. It should be noted that many of these
structures were not observed in early stages of ovarian
cancer and/or healthy controls. However, all these structures
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FIGURE 1 | (A) Representative MALDI-TOF mass spectrum of the serum N-glycans of an ovarian cancer patient after linkage-specific sialic acid derivatization.
(B) Enlargement of the region 2,850–3,250 Da. Measurements were performed in the positive-ion mode and all molecular ions are present in sodiated form [M +
Na]+. Dark gray circle, Man; light gray circle, Gal; black square, GlcNAc; dark gray triangle, Fuc; dark gray diamond, Neu5Ac.
were included in statistical analysis due to their possible
biological significance.
Relative intensities of 71 glycans were normalized to
the base peak intensity. Means and standard deviations
(SD) were calculated for healthy controls and all FIGO
stages and are presented in Table 2. Thereafter, N-
glycans were grouped according to type, antennarity,
fucosylation and sialylation. Moreover, their relative
abundances were statistically compared between healthy
controls, early and late stages, whereby the post-hoc
statistical test is reported for the total traits only
(Supplementary Tables 2–10).
The statistical analysis of sialylated complex-type
structures was first performed on a single glycan level
followed by calculation of glycan traits as explained in
the Materials and Methods section. The complex-type
sialylated structures are presented here separately based
on their fucose content. Additionally, for both fucosylated
and afucosylated structures, total glycosylation traits were
calculated, such as relative antennarity. It should be noted
that while total α-2,6-linked sialylation is pretty similar
to a total sialylation relative intensity, the relative α-2,3-
linked sialylation shows different patterns (data not shown).
Therefore, a ratio between α-2,3-linked sialylation and α-
2,6-linked sialylation was calculated. In the following, “total
sialylation” refers to the whole sialylation irrespective of the
linkage types, whereas “sialylation ratio” refers to the ratio
α-2,3-linked /α-2,6-linked sialylated structures as defined in
Supplementary Table 1.
Decrease of N-glycans: High-Mannose,
Hybrid, Complex-Type Asialylated, Mono-,
Di-, Triantennary Sialylated Structures
High-Mannose N-glycans
The TJT showed that there was a statistically significant negative
trend in mean rank distribution of N2H5 and N2H6 for both
grouped (early and late) FIGO stages (Supplementary Table 2).
The post-hoc analysis of the TJT test revealed that there
was a highly significant decrease in total high-mannosylation
between healthy controls and late stage patients, and between
early stage and late stage patients (Figure 2A). There was no
statistically significant difference between healthy controls and
early stage patients.
Hybrid-Type Sialylated N-glycans
Statistical analysis revealed a significant decrease in both α-
2,3- and α-2,6-sialylation forms of hybrid structure N3H5S1
(Supplementary Table 3) as well as a significant increase in
the α-2,3-isomer of N3H6S1. For the total relative intensity of
hybrid structures, there was a statistically significant decrease.
The post-hoc analysis revealed that there were statistically
significant decreases between healthy controls and late stage
patients, and between early stage and late stage patients but no
statistically significant difference between healthy controls and
early stage patients.
Neutral Afucosylated Complex-Type N-glycans
There were statistically significant differences for all
complex-type neutral N-glycans, except for N4H3. Similarly to
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TABLE 2 | Mean relative intensities (normalized to the base peak intensity) and SD of all detected structures across ovarian cancer stages measured by MALDI-TOF-MS.
Glycan Mass
[m/z]
Healthy control Figo I Figo II Figo III Figo IV
Mean SD Mean SD Mean SD Mean SD Mean SD
High-mannose N2H5 1257.4 2.06 1.31 2.48 0.69 1.39 0.48 0.86 0.45 0.75 0.44
N2H6 1419.5 1.46 1.02 1.99 0.72 1.36 0.46 0.95 0.51 0.87 0.58
N2H7 1581.5 0.19 0.19 0.50 0.25 0.32 0.15 0.25 0.20 0.24 0.20
N2H8 1743.6 0.37 0.21 0.61 0.37 0.49 0.17 0.40 0.24 0.36 0.24
Complex N3H4 1298.4 0.18 0.21 0.25 0.24 0.15 0.16 0.07 0.10 0.08 0.09
N4H3 1339.5 0.37 0.70 0.53 0.34 0.29 0.26 0.23 0.26 0.23 0.24
N4H5 1663.6 0.73 0.43 0.53 0.12 0.38 0.18 0.24 0.16 0.23 0.15
N5H4 1704.6 0.16 0.29 0.36 0.18 0.20 0.10 0.23 0.18 0.21 0.16
N5H5 1866.7 0.04 0.07 0.14 0.17 0.08 0.08 0.09 0.11 0.07 0.09
N5H6 2028.7 0.00 0.01 0.02 0.06 0.01 0.04 0.02 0.04 0.03 0.05
Complex fucosylated N4H3F1 1485.5 5.22 3.15 10.49 4.51 8.05 6.05 9.19 12.36 6.20 4.05
N4H4F1 1647.6 5.19 2.51 8.16 3.93 4.99 3.13 4.45 3.89 3.58 2.37
N4H5F1 1809.6 1.60 0.89 1.98 1.33 1.23 1.05 0.90 0.84 0.72 0.62
N5H4F1 1850.7 1.03 0.43 1.42 0.54 0.86 0.40 0.77 0.61 0.63 0.42
N5H5F1 2012.7 0.15 0.10 0.29 0.20 0.13 0.11 0.14 0.15 0.13 0.10
N5H5F2 2158.8 0.50 0.13 0.72 0.21 0.54 0.17 0.56 0.26 0.59 0.24
N5H6F1 2174.8 0.01 0.02 0.07 0.12 – – 0.03 0.05 0.01 0.02
Complex sialylated N3H4A1 1588.6 0.01 0.02 0.54 0.79 0.21 0.25 0.46 0.47 0.42 0.48
N3H4D1 1616.6 1.75 0.51 1.33 0.33 0.89 0.21 0.82 0.33 0.88 0.33
N3H5A1 1750.6 1.93 0.75 2.03 0.60 1.63 0.46 1.11 0.54 0.85 0.61
N3H5D1 1778.6 0.47 0.20 0.49 0.08 0.33 0.08 0.26 0.13 0.25 0.10
N4H4A1 1791.6 0.04 0.16 0.77 1.10 0.32 0.36 0.68 0.70 0.58 0.68
N4H4D1 1819.7 0.71 0.28 0.73 0.30 0.46 0.12 0.53 0.28 0.52 0.28
N3H6A1 1912.7 0.02 0.08 0.11 0.15 0.01 0.04 0.05 0.09 0.05 0.10
N3H6D1 1940.7 0.10 0.08 0.12 0.07 0.05 0.06 0.09 0.07 0.07 0.06
N4H5A1 1953.7 0.28 0.13 0.54 0.44 0.28 0.16 0.43 0.32 0.37 0.32
N4H5D1 1981.7 12.00 2.65 10.52 2.12 8.38 2.60 7.51 2.89 8.32 3.13
N5H5D1 2184.8 0.36 0.22 0.51 0.20 0.31 0.15 0.25 0.15 0.27 0.13
N4H5A2 2243.8 0.09 0.10 0.14 0.11 0.04 0.08 0.02 0.05 0.04 0.05
N4H5D1A1 2271.8 3.77 1.27 3.80 0.64 3.26 1.14 3.09 1.08 2.99 1.02
N4H5D2 2299.9 100.00 – 100.00 – 100.00 – 100.00 – 100.00 –
N5H6A1 2318.8 0.16 0.29 – – 0.12 0.14 0.13 0.22 0.11 0.11
Complex sialylated N5H6D1 2346.9 0.45 0.21 0.44 0.11 0.42 0.15 0.29 0.17 0.32 0.13
N5H5D2 2502.9 0.27 0.15 0.42 0.11 0.32 0.42 0.21 0.23 0.28 0.28
N5H6D1A1 2637.0 0.47 0.23 0.49 0.12 0.42 0.22 0.35 0.16 0.32 0.15
N5H6D2 2665.0 0.64 0.24 0.64 0.16 0.52 0.23 0.39 0.17 0.42 0.11
N5H6A3 2899.0 – – 0.04 0.07 – – 0.03 0.05 0.03 0.05
N5H6D1A2 2927.1 0.30 0.25 0.32 0.15 0.31 0.21 0.29 0.17 0.26 0.19
N5H6D2A1 2955.1 6.41 3.07 5.58 2.32 5.22 2.99 4.42 2.35 3.71 2.44
N5H6D3 2983.1 2.15 0.64 2.93 1.16 2.94 1.65 2.20 0.75 2.28 0.63
N6H7D1A1 3002.1 0.08 0.10 0.24 0.09 0.22 0.17 0.12 0.09 0.11 0.07
N6H7D2 3030.1 0.01 0.03 0.07 0.10 0.04 0.08 0.04 0.05 0.05 0.05
N6H7D1A2 3292.2 0.04 0.06 0.09 0.09 0.09 0.11 0.08 0.09 0.07 0.08
N6H7D2A1 3320.2 0.05 0.08 0.14 0.12 0.09 0.14 0.09 0.09 0.07 0.06
N6H7D1A3 3582.3 0.03 0.06 0.05 0.09 0.10 0.14 0.12 0.14 0.11 0.15
N6H7D2A2 3610.3 0.14 0.12 0.18 0.16 0.24 0.23 0.22 0.17 0.19 0.20
N6H7D3A1 3638.4 0.01 0.04 0.07 0.09 0.08 0.11 0.08 0.09 0.08 0.08
Complex sialylated fucosylated N4H5A1F1 2099.7 0.24 0.10 0.23 0.11 0.14 0.12 0.14 0.10 0.17 0.09
N4H5D1F1 2127.8 2.22 0.84 2.28 1.14 1.55 0.88 1.21 0.75 1.24 0.61
(Continued)
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TABLE 2 | Continued
Glycan Mass
[m/z]
Healthy control Figo I Figo II Figo III Figo IV
Mean SD Mean SD Mean SD Mean SD Mean SD
N5H5D1F1 2330.9 0.94 0.50 1.51 0.89 0.86 0.64 0.67 0.56 0.66 0.31
N4H5A2F1 2389.9 0.54 0.28 0.62 0.18 0.60 0.20 0.37 0.20 0.22 0.16
N4H5D1A1F1 2417.9 0.54 0.21 0.66 0.16 0.82 0.55 0.74 0.32 0.91 0.55
N4H5D2F1 2445.9 4.46 1.15 3.40 1.19 3.56 0.94 2.71 1.05 3.10 1.21
N5H6D1F1 2492.9 0.05 0.09 0.15 0.15 0.05 0.09 0.02 0.05 0.03 0.05
N5H5D1A1F1 2621.0 0.01 0.03 0.07 0.10 0.02 0.05 0.03 0.05 0.03 0.04
N5H5D2F1 2649.0 1.48 0.72 1.55 0.57 1.31 0.80 0.99 0.51 0.93 0.35
N5H6D1A1F1 2783.0 0.06 0.10 0.18 0.12 0.20 0.14 0.12 0.13 0.19 0.12
N5H6D2F1 2811.1 0.09 0.10 0.17 0.11 0.17 0.11 0.07 0.09 0.13 0.09
N5H6D1A2F1 3073.1 0.05 0.07 0.21 0.15 0.25 0.17 0.21 0.13 0.21 0.15
N5H6D2A1F1 3101.2 2.12 1.06 4.59 2.06 6.37 3.45 5.05 2.46 5.48 2.72
N5H6D3F1 3129.2 0.12 0.12 0.22 0.14 0.27 0.17 0.15 0.12 0.18 0.11
N6H7D1A1F1 3148.2 – – 0.05 0.10 0.06 0.11 0.04 0.07 0.08 0.07
N5H6D1A2F2 3219.2 – – 0.01 0.04 0.08 0.12 0.05 0.08 0.08 0.08
N5H6D2A1F2 3247.2 0.01 0.04 0.04 0.10 0.14 0.14 0.06 0.10 0.11 0.09
N6H7D1A2F1 3438.3 – – – – 0.07 0.11 0.03 0.06 0.08 0.07
N6H7D2A1F1 3466.3 – – 0.01 0.03 0.05 0.11 0.03 0.06 0.06 0.07
N6H7D1A3F1 3728.4 – – – – 0.11 0.13 0.08 0.12 0.11 0.14
N6H7D2A2F1 3756.4 0.02 0.04 0.08 0.11 0.25 0.20 0.23 0.19 0.22 0.21
N6H7D3A1F1 3784.4 – – 0.01 0.03 0.03 0.06 0.06 0.10 0.08 0.08
N6H7D1A3F2 3874.4 – – 0.01 0.04 0.03 0.07 0.03 0.06 0.05 0.08
N6H7D2A2F2 3902.5 – – – – 0.10 0.18 0.07 0.13 0.11 0.11
FIGURE 2 | Mean and 95% confidence intervals of N-glycans grouped by type, antennarity, sialylation, and fucosylation during ovarian cancer progression.
(A) High-mannose type total; (B) complex type afucosylated neutral total; (C) monoantennary sialylated total; (D) biantennary complex total; (E) biantennary sialylated
fucosylated total; (F) triantennary sialylated total. *p < 0.05, **p < 0.01, ***p < 0.001.
the high-mannosylation, there was a highly significant decrease
in total relative intensity of afucosylated complex-type N-
glycans (Supplementary Table 4) but no statistically significant
difference between healthy controls and early stage patients
(Figure 2B). Additionally, there was a statistically significant
decrease of monoantennary and biantennary N-glycans
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(N3H4, N4H5) and increase of triantennary N-glycans (N5H4,
N5H5, N5H6).
Neutral Fucosylated Complex-Type N-Glycans
The complex-type core-fucosylated structures that are present for
instance on IgG, namely N4H4F1, N4H5F1 showed statistically
significant decreases in relative intensities between healthy
controls and ovarian cancer stages, but there was no statistically





A statistically significant negative trend was observed for
N3H4D1, the α-2,6-linked isomer, and a statistically positive
trend for N3H4A1, the α-2,3-linked isomer. The total relative
intensity for monoantennary sialylated structures decreased in
advanced cancer stages (Supplementary Table 6). The post-hoc
analysis revealed that there were statistically significant decreases
between healthy controls and early stage patients, and between
healthy controls and late stage patients. There was no statistically
significant difference between early and late stage patients
(Figure 2C). The total relative intensity for both fucosylated
and afucosylated biantennary sialylated glycans and triantennary
sialylated significantly decreased in ovarian cancer compared
to healthy controls (Supplementary Table 7; Figures 2D–F).
Significant differences were observed between healthy controls
and late stage patients, between early stage and late stage patients
but not between healthy controls and early stage patients.
Increase of α-2,3/α-2,6-sialylation Ratios, a
Marker for Early and Late Stage EOC
α-2,3/α-2,6-sialylation Ratios of Biantennary
Sialylated N-glycans
The α-2,3/α-2,6-sialylation ratio significantly increases for
both afucosylated and fucosylated N-glycans in ovarian cancer
patients (Supplementary Table 7; Figures 3A,B). Post-hoc
analysis showed statistically significant increases between
healthy control and early stage and between healthy controls and
late stage patients.
α-2,3/α-2,6-sialylation Ratios of Triantennary
Sialylated N-glycans
There was a statistically significant increase in α-2,3-linked/
α-2,6-linked sialylation ratio of fucosylated triantennary N-
glycans, which was observed between healthy controls and both
early stage and late stage ovarian cancer patients (Figure 3C,
Supplementary Table 8).
α-2,3/α-2,6-sialylation Ratios of Tetrantennary
Sialylated N-glycans
There was a statistically significant increase in relative intensities
of three tetraantennary N-glycans, namely N6H7D2, N6H7D1A3
and N6H7D3A1 (Supplementary Table 9) but the ratio between
α-2,3 and α-2,6 sialylation did not vary significantly for both
afucosylated and fucosylated N-glycans in all three cohorts. This
could be due to steric the hindrance of α-2,3-linkages, which
theoretically favors mixed α-2,3 / α-2,6 sialic acid linkages.
α-2,3/α-2,6-sialylation Ratios of Fucosylated and
Afucosylated Stuctures
There were highly significant increases in sialylation ratios
for both afucosylated and fucosylated N-glycans, namely
between healthy control and both early stage and late stage
(Supplementary Table 10; Figures 3D,E). These changes in α-
2,3 / α-2,6 sialylation ratio appear to be cancer specific, since
in both fucosylated and afucosylated glycans are observed
statistically significant differences between healthy controls and
cancer stages. Moreover, there were no statistically significant
differences between early and late stage ovarian cancer patients,
which makes these ratios a possible candidate for improving
ovarian cancer diagnostics.
α-2,3/α-2,6-sialylation Ratios of All Sialylated
N-glycan Structures
On the total sialylation level, when the ratio α-2,3/α-2,6 was used,
there were statistically significant increases between all three
cohorts, namely between healthy controls and both early and late
stages of ovarian cancer and between early and late stage patients
(TJT = 743, z = 2.269, p = 0.035) (Supplementary Table 10;
Figure 2F).
α-2,3/α-2,6-sialylation Ratios as Enhancement of
Ovarian Cancer Diagnosis
Since the changes in sialylation ratio showed statistically
significant differences between healthy controls and all
primary serous ovarian cancer patients of epithelial origin,
the values were used for the construction of receiver operating
characteristic (ROC) curves (Supplementary Figure 2), using
SPSS for Windows, version 21 (SPSS Inc., Chicago, Ill), to
evaluate possible application in ovarian cancer diagnostics.
Supplementary Figure 2A shows ROC curves for early stage
patients vs. controls whereas Figure 2B presents ROC curves for
all EOC patients vs. healthy controls.
The ratios for separate groups based on antennarity and
fucosylation showed ROC curves with areas under the curve
(AUC) from 0.717 to 0.887, which is a “good” result. The AUC
for total sialylation ratio showed the best results for both early
stage and all patients: 0.88 (Supplementary Figure 2A) and 0.911
(Supplementary Figure 2B), respectively, however, AUC values
were still lower than for the routinely used CA125 (AUC =
0.953). The software MedCalc (Version 18.6) was then used
to evaluate the cut-off value of total sialylation ratio based on
Youden index (J = 0.7576) and the calculated cut-off value of
0.2424 was estimated (Supplementary Figure 1).
Since the total sialylation ratio showed the best results, it was
tested whether the combination of sialylation ratio with CA125
could improve ovarian cancer diagnostic. A logistic regression
was performed to evaluate the potential of CA125 and sialylation
ratio on the ovarian cancer diagnosis. The prediction model was
as follows: −10.553 + 0.108∗CA125 + 33.062∗ratio. The logistic
regression model was statistically significant [χ2
(4)
= 101.402, p
< 0.001], explained 85.4% (Nagelkerke R2) of the variance in
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FIGURE 3 | Mean and 95% confidence intervals of α-2,3/α-2,6 ratio of N-glycans grouped by antennarity and fucosylation during ovarian cancer progression.
(A) Biantennary afucosylated ratio; (B) biantennary fucosylated ratio; (C) triantennary fucosylated ratio; (D) all afucosylated ratio; (E) all fucosylated ratio; (F) all
sialylated ratio. *p < 0.05, **p < 0.01, ***p < 0.001.
ovarian cancer and correctly classified 88.2% of cases. Therefore,
ROC curves were plotted for the combined probability results
and the final AUC were 0.954 for early stage (Figure 4A) and
0.985 (Figure 4B) for all patients, respectively, which means a
“very good” classification.
These results suggest that information about sialylation
linkages provides cancer-specific insight and may refine the
measurement of CA125 both in early stage and in late stage EOC
patients as the combination of both resulted in an improvement
of the specificity and the sensitivity.
DISCUSSION
In the present study, we focused on the analysis of sialic
acid linkages from primary serous ovarian cancer patients in
early (FIGO I + II) and late stages (FIGO III + IV) of
the disease to age-matched healthy controls. N-Glycans from
serum samples were released by PNGase F and sialic acids were
stabilized by linkage-specific labeling (18) before MALDI-TOF-
MS measurement.
High-mannose and neutral complex-type N-glycan structures
showed statistically significant differences only between healthy
patients and late stage ovarian cancer patients and no differences
between healthy controls and early stage patients. Additionally,
increases of antennarity were observed here that correspond
with the published literature, since increased expression of
GlcNAcT IV and V leads to increased branching and thus
antennarity (21, 22).
Interestingly, in this study, N4H3F1, the agalactosylated
N-glycan present on IgG (23), the most abundant serum
glycoprotein, did not show any statistical difference whereas its
galactosylated forms N4H4F1 and N4H5F1 were significantly
decreased. Saldova and colleagues (15) showed using ovarian
cancer samples, irrespective of FIGO stages, that there was a
decrease of IgG galactosylation and an increase of agalactosyl
IgG N-glycans in ovarian cancer patients. However, it should
be noted that our analysis was performed on 110 whole serum
N-glycome samples and not at the IgG level alone. This is the
reason why the observed changes can only be partly explained by
the IgG glycosylation alone. Compared to the above-mentioned
publication, our findings suggest an initial increase of relative
abundance of total complex fucosylated N-glycans in early
FIGO stages, followed by a decrease in late stages. This could
be explained by inflammation and greater IgG production in
early stages, thus greater abundance of glycan structures carried
on IgG.
The majority of sialylation traits showed specificity for
ovarian cancer already in early stage, which is desired for
potential biomarker use. On the level of total sialylation,
regardless of the linkage type, a statistically significant decrease
was observed for monoantennary afucosylated N-glycans. In
contrast, triantennary fucosylated N-glycans and tetraantennary
N-glycans both fucosylated and afucosylated showed statistically
significant increase. Since the changes in relative intensities
without the focus on sialic acid linkages has been extensively
studied in recent years in various malignancies (5, 15, 17, 24–28),
these will not be discussed further here.
More importantly, the information about sialic acid linkage
ratios always showed statistically significant differences already
for early stage EOC. When classified according to the
antennarity, there was statistically significant increase in α-
2,3/α-2,6 ratio for biantennary afucosylated and fucosylated
N-glycans, and triantennary fucosylated N-glycans. Similarly,
there was a statistically significant increase in α-2,3/ α-2,6 ratio
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FIGURE 4 | ROC curves generated for (A) 33 healthy controls and 19 early-stage patients; (B) 33 healthy controls and 77 ovarian cancer patients.
of all afucosylated and fucosylated sialylated N-glycans. Most
importantly, the increase in α-2,3/ α-2,6 ratio of all sialylated
N-glycans showed statistically significant differences between all
three cohorts.
In many publications (5, 17, 25, 27), the glycan structure
N5H6S3F1 was significantly increased in malignancies. This
structure has four potential sialylation isomers, namely
N5H6A3F1, N5H6A2D1F1, N5H6A1D2F1, and N5H6D3F1.
Interestingly, in the present study only structures with mixed
sialylation, e.g., N5H6A2D1F1, N5H6A1D2F1 show statistically
significant increase in ovarian cancer. On the other hand, the
structure N5H6D3F1 showed no differences between healthy
controls and ovarian cancer patients and N5H6A3F1 could not
be detected in any cohort. The increase of N5H6A1D2F1 is
accompanied by statistically significant decrease of N5H6A1D2.
These changes correlate with findings that synthesis of SLex
antigen requires first addition of sialic acid, followed by addition
of antennary fucose (29).
The observed changes in ovarian cancer serum sialylation
agree with findings in other types of cancer. Holst et al. showed by
MALDI-Imaging in colorectal carcinoma, that the α-2,3-linked
sialic acid was increased in stroma, tumor, and necrotic cell
regions, while α-2,6-linked sialic acid was more prominent in
inflammatory areas, e.g., rich in collagen, necrotic regions and
red-blood cells (18). On some colorectal cancer cell lines (HT29,
WiDr, SW48, T84, and Lovo) an increased α-2,3-sialylation
was observed together with multiple fucosylation (30). Saldova
et al. observed increased α-2,3-sialylation in prostate cancer as
compared to benign hyperplasia (31). In the study performed
by Wang and colleagues (32), increased mRNA expression of
ST3Gal III, ST3Gal IV, and ST3Gal VI was observed in ovarian
serous carcinoma tissues. Moreover, immunohistochemical
staining using the lectin maackia amurensis agglutinin showed
strong positivity in ovarian epithelial carcinoma part, while
normal epithelial part was not. Wen et al. then studied expression
of ST3Gal I in serous type epithelial ovarian cancer (33) and in
clear cell type epithelial ovarian cancer (34). They proposed α-
2,3-sialylation as a potential prognostic marker and a possible
therapy target of ovarian cancer.
The sialylation changes were reported here as a ratio between
relative α-2,3-sialylation and α-2,6-sialylation. In general, glycans
containing exclusively α-2,3-linked sialic acids were not observed
in the samples in high amounts and structures carrying both
linkage types were most prominent in tri- and tetraantennary
structures. This is most likely an effect of steric hindrance.
However, there was an increase in the relative α-2,3-sialylation
in ovarian cancer samples as compared to healthy controls.
Moreover, the relative α-2,3-linked sialylation increased with
increasing antennarity and cancer stage, reaching its maximum
in tetraantennary structures (50%).
Since the increase in total α-2,3/α-2,6-sialylation ratio was
statistically significant for ovarian cancer, ROC curves were
generated for sialylation ratios, the CA125 biomarker and for
the binary logistic regression model of the combination of
CA125 with the total sialylation ratio. The proposed model
could improve the classification of both early- and late-stage
ovarian cancer patients compared to CA125 alone. While CA125
alone showed a sensitivity of 84.4% and a specificity of 97%,
in combination with the sialylation ratio, both sensitivity and
specificity increased to 89.6% and 100%, respectively.
The advantage of such an approach lies in the utilization
of a biomarker, which is already used all over the world in
clinical laboratories, whose sensitivity and specificity could be
improved by an additional measurement of glycosylation. Such
a measurement could be proposed in unclear cases and/or cases
below certain cut-off value of CA125. Since the results observed
here were obtained from the whole serum N-glycome, it is
unclear, which glycoproteins contributed to the changes, however
the increased α-2,3-sialylation clearly correlated with ovarian
cancer stage. A further sialylation study of specific proteins, such
as acute-phase proteins, could shed light on the pathogenesis of
ovarian cancer.
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